Shop by goal

Popular compounds

GHK-Cu

Retatrutide

Tirzepatide

Semaglutide

All bestsellers →

Research resources

Certificates of Analysis

Tesamorelin: HGH / Somatropin research guide

Q: What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) stabilised with an N-terminal hexenoic acid. It signals the pituitary to release growth hormone and is the molecule approved (as Egrifta) to reduce excess visceral fat in HIV-associated lipodystrophy. New-U's tesamorelin is research-grade material supplied for laboratory use only — not the approved drug and not for human use.

Q: What does tesamorelin do?

In the research and clinical literature tesamorelin activates the pituitary GHRH receptor to raise growth hormone and IGF-1, with a notable effect on visceral (deep abdominal) adipose tissue. These are findings for the molecule; New-U supplies research-grade tesamorelin for laboratory research only and implies no human therapeutic effect.

Q: What is tesamorelin used for?

Clinically the approved drug is used to reduce visceral fat in HIV-associated lipodystrophy. In the research literature it is a tool compound for GH-axis and adipose-tissue studies. New-U supplies research-grade tesamorelin strictly for in-vitro and animal-model research, not for human use.

Q: Is tesamorelin FDA approved?

The pharmaceutical tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. That approval applies to the finished prescription drug — NOT to research-grade material. New-U's tesamorelin is an unapproved research powder supplied for laboratory research only and is not a substitute for the prescription product.

Q: Is tesamorelin safe?

As the approved drug Egrifta, tesamorelin has a human safety dataset under medical supervision. That record does not extend to research-grade material, which is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use claims.

Q: How is tesamorelin different from sermorelin or CJC-1295?

All three are GHRH analogs, but tesamorelin is a full 44-amino-acid version with an N-terminal hexenoic acid for DPP-IV resistance. Sermorelin is the shorter 29-residue truncation with a shorter half-life, and CJC-1295 uses either tetrasubstitution (no-DAC) or covalent albumin binding (DAC) for different duration profiles. Tesamorelin has the strongest clinical dataset.

Q: Tesamorelin vs ipamorelin — what is the difference?

They act on opposite ends of the same axis: tesamorelin is a GHRH-receptor analogue acting upstream on the pituitary, while ipamorelin is a selective ghrelin-receptor (GHSR) agonist. Tesamorelin has the heavier clinical dataset and a specific visceral-fat signal, whereas ipamorelin is prized for clean GH release with minimal cortisol or prolactin effect. Because they engage different receptors, the two are studied together as a complementary GHRH + secretagogue pairing rather than as substitutes.

Q: Why does tesamorelin reduce visceral fat specifically?

GH itself preferentially mobilises visceral adipose tissue because visceral fat is more sensitive to catecholamine and GH-driven lipolysis than subcutaneous fat. Tesamorelin generates a physiologic GH pulse that targets exactly this compartment, which is why VAT drops while SAT is largely preserved.

Q: Does tesamorelin raise blood sugar?

Like any GH-driven protocol, tesamorelin can transiently raise fasting glucose and worsen insulin sensitivity because GH opposes insulin action. Clinical trials reported modest glycemic changes that are typically manageable but warrant monitoring in research protocols.

Q: How should tesamorelin be stored?

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C, protect from light, and use within the peptide's typical stability window. Avoid shaking, which can denature the peptide.

Not medical advice. Tesamorelin is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

What Tesamorelin is

Tesamorelin is an FDA-approved synthetic GHRH(1-44) analog engineered for DPP-IV resistance, studied for visceral fat reduction, IGF-1 elevation, and metabolic research.

One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.

Tesamorelin, FDA-approved synthetic GHRH(1-44) analogue with N-terminal hexenoic acid modification for DPP-IV resistance and pulsatile GH release.

Research contexts

Peer-reviewed literature typically discusses Tesamorelin in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.

Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.

Typical study contexts

Pituitary GH release patterns, receptor signalling, and metabolic readouts in compliant animal research.

Comparisons between secretagogues and exogenous GH in model organisms, focusing on endocrine biology.

Peer-reviewed preclinical work sometimes describes experiments that track whether activates GHRH receptors on pituitary somatotrophs to stimulate endogenous pulsatile GH secretion

Peer-reviewed preclinical work sometimes describes experiments that track whether n-terminal trans-3-hexenoic acid modification confers DPP-IV protease resistance extending functional duration

Peer-reviewed preclinical work sometimes describes experiments that track whether fDA-approved for reduction of visceral adipose tissue in HIV-associated lipodystrophy

Peer-reviewed preclinical work sometimes describes experiments that track whether preserves hypothalamic-pituitary GH axis feedback via somatostatin-regulated pulsatility

Why HGH / Somatropin research matters

Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.

Mechanisms (technical review)

Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.

Activates GHRH receptors on pituitary somatotrophs to stimulate endogenous pulsatile GH secretion

N-terminal trans-3-hexenoic acid modification confers DPP-IV protease resistance extending functional duration

FDA-approved for reduction of visceral adipose tissue in HIV-associated lipodystrophy

Preserves hypothalamic-pituitary GH axis feedback via somatostatin-regulated pulsatility

Elevates IGF-1 levels 1.5–3-fold supporting downstream anabolic and metabolic signaling

Investigated for reduction of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease

Lab handling & preparation

Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.

Research dosing context: Literature typically discusses 1–2 mg daily subcutaneously (research vials supplied at 5 mg or 10 mg) · Once daily subcutaneous injection · Elimination t½ ≈ 8–26 min; Tmax = 0.15 h (median); absolute bioavailability <4% (SC); GH pulse duration 2–4 h post-injection; IGF-1 elevation accumulates over weeks of repeated dosing. AUC 34% higher in HIV-infected patients vs. healthy subjects.

Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.

Common Questions People Are Asking

What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) stabilised with an N-terminal hexenoic acid. It signals the pituitary to release growth hormone and is the molecule approved (as Egrifta) to reduce excess visceral fat in HIV-associated lipodystrophy. New-U's tesamorelin is research-grade material supplied for laboratory use only — not the approved drug and not for human use.

What does tesamorelin do?

In the research and clinical literature tesamorelin activates the pituitary GHRH receptor to raise growth hormone and IGF-1, with a notable effect on visceral (deep abdominal) adipose tissue. These are findings for the molecule; New-U supplies research-grade tesamorelin for laboratory research only and implies no human therapeutic effect.

What is tesamorelin used for?

Clinically the approved drug is used to reduce visceral fat in HIV-associated lipodystrophy. In the research literature it is a tool compound for GH-axis and adipose-tissue studies. New-U supplies research-grade tesamorelin strictly for in-vitro and animal-model research, not for human use.

Is tesamorelin FDA approved?

The pharmaceutical tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. That approval applies to the finished prescription drug — NOT to research-grade material. New-U's tesamorelin is an unapproved research powder supplied for laboratory research only and is not a substitute for the prescription product.

Is tesamorelin safe?

As the approved drug Egrifta, tesamorelin has a human safety dataset under medical supervision. That record does not extend to research-grade material, which is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use claims.

How is tesamorelin different from sermorelin or CJC-1295?

All three are GHRH analogs, but tesamorelin is a full 44-amino-acid version with an N-terminal hexenoic acid for DPP-IV resistance. Sermorelin is the shorter 29-residue truncation with a shorter half-life, and CJC-1295 uses either tetrasubstitution (no-DAC) or covalent albumin binding (DAC) for different duration profiles. Tesamorelin has the strongest clinical dataset.

Tesamorelin vs ipamorelin — what is the difference?

They act on opposite ends of the same axis: tesamorelin is a GHRH-receptor analogue acting upstream on the pituitary, while ipamorelin is a selective ghrelin-receptor (GHSR) agonist. Tesamorelin has the heavier clinical dataset and a specific visceral-fat signal, whereas ipamorelin is prized for clean GH release with minimal cortisol or prolactin effect. Because they engage different receptors, the two are studied together as a complementary GHRH + secretagogue pairing rather than as substitutes.

Why does tesamorelin reduce visceral fat specifically?

GH itself preferentially mobilises visceral adipose tissue because visceral fat is more sensitive to catecholamine and GH-driven lipolysis than subcutaneous fat. Tesamorelin generates a physiologic GH pulse that targets exactly this compartment, which is why VAT drops while SAT is largely preserved.

Does tesamorelin raise blood sugar?

Like any GH-driven protocol, tesamorelin can transiently raise fasting glucose and worsen insulin sensitivity because GH opposes insulin action. Clinical trials reported modest glycemic changes that are typically manageable but warrant monitoring in research protocols.

How should tesamorelin be stored?

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C, protect from light, and use within the peptide's typical stability window. Avoid shaking, which can denature the peptide.

What happens if you stop taking peptides?

Tesamorelin is a GHRH analogue studied for its effect on visceral fat via the body's own GH release. The published clinical literature on the reference drug reports that the visceral-fat reduction is not maintained after the peptide is discontinued — visceral adipose tissue tends to return toward baseline — because the effect depends on ongoing GH-axis stimulation rather than a permanent change. Those findings describe the approved medicine in human studies; tesamorelin here is an unapproved research-grade peptide for laboratory research only and is not for human use.

Is this page medical advice? Can I use Tesamorelin for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Tesamorelin specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Tesamorelin.

HGH 191 AA - companion guide

Sermorelin - companion guide

HGH Fragment 176-191 - companion guide

CJC-1295 (with DAC) - companion guide

Scientific sources & further reading

Primary literature and registries for Tesamorelin, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Tesamorelin

ClinicalTrials.gov: registered studies on Tesamorelin

Tesamorelin: Wikipedia

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: TH-9507, Growth Hormone Releasing Factor 1-44 Analogue, trans-3-Hexenoic Acid GHRH, Tesamorelin Acetate

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.